At the end of December 2025, China Resources Double-Crane Biomedical Industry Fund (Hohhot) Investment Partnership (Limited Partnership) and China Resources (Chengdu) Pharmaceutical Industry Investment Fund Partnership (Limited Partnership) completed their registration with the Asset Management Association of China (AMAC). Both funds are managed by CR Capital MGMT.
China Resources Double-Crane Biomedical Industry Fund (Hohhot) Investment Partnership (Limited Partnership) was established in Hohhot City jointly by CR Capital MGMT, CR Double-Crane, and CR PHARMA, alongside the Hohhot Municipal People's Government's investment platform, with a total capital of RMB 500 million. As the first fund established by CR Group to specialize in the synthetic biology sector, it will prioritize investments in cutting-edge fields such as synthetic biology, focusing on the commercialization of core technologies and advanced scientific and technological achievements. The fund primarily targets growth-stage and merger and acquisition (M&A) projects.
China Resources (Chengdu) Pharmaceutical Industry Investment Fund Partnership (Limited Partnership) was established in Chengdu jointly by CR Capital MGMT and CR PHARMA, in collaboration with CR Double-Crane, CR Jiangzhong, Dong-E-E-Jiao, CR BOYA-BIO, and external partners, including Chengdu Major Industrialization Project Investment Fund, Chengdu Future Industry Venture Capital Guidance Fund, Chengdu Orinno Fund, Chengdu Bio-town Equity Investment Fund, and Fosun Pharma, with a total capital of RMB 1 billion. It will focus on investments in sectors such as innovative chemical drugs, biologics, high-end medical devices, traditional Chinese herbal tonics, and synthetic biology.
Since 2017, CR Capital MGMT has initiated and managed multiple industry funds in collaboration with CR's industrial business units. These include Runke Microelectronics Fund (Phase I), Runchuang New Energy Fund, and CR PHARMA Industry Investment Fund, consistently assisting CR's industrial sectors in optimizing investment layouts and cultivating new growth drivers through fund vehicles. In December 2025, the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, with participation from CR Capital MGMT, was registered and established in Shenzhen. This fund leverages industrial ecosystems to empower technological innovation and upgrades.
As the "fund business management platform" and "direct investment platform for strategic emerging industries" under CR Group, CR Capital MGMT has remained committed to serving national strategies, implementing the Group's plans, and fully leveraging the functions and values as a dual platform to continuously provide impetus to the high-quality development of CR Group's businesses.
